Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)

China flag China · Delayed Price · Currency is CNY
4.880
+0.030 (0.62%)
Mar 26, 2026, 3:04 PM CST
Market Cap5.12B +27.0%
Revenue (ttm)775.69M -2.5%
Net Income-134.71M
EPS-0.13
Shares Out1.06B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume21,288,411
Average Volume25,015,033
Open4.840
Previous Close4.850
Day's Range4.820 - 4.980
52-Week Range2.770 - 6.140
Beta0.28
RSI49.69
Earnings DateMar 19, 2026

About SHE:300006

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Chongqing, China. [Read more]

Sector Healthcare
Founded 1999
Employees 1,019
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300006
Full Company Profile

Financial Performance

In 2025, SHE:300006's revenue was 775.69 million, a decrease of -2.50% compared to the previous year's 795.60 million. Losses were -134.71 million, 53.4% more than in 2024.

Financial Statements